 Joshua Solomon
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 44 | 2025 | 638 | 10.450 |
Why?
| | Arthritis, Rheumatoid | 29 | 2025 | 1167 | 5.320 |
Why?
| | Idiopathic Pulmonary Fibrosis | 14 | 2025 | 657 | 2.530 |
Why?
| | Connective Tissue Diseases | 9 | 2022 | 84 | 1.970 |
Why?
| | Pulmonary Fibrosis | 6 | 2025 | 402 | 1.880 |
Why?
| | Dyspnea | 3 | 2025 | 254 | 1.780 |
Why?
| | Tomography, X-Ray Computed | 11 | 2025 | 2691 | 1.520 |
Why?
| | Myositis | 3 | 2024 | 52 | 1.190 |
Why?
| | Immunoglobulin A | 2 | 2020 | 211 | 1.190 |
Why?
| | Autoantibodies | 8 | 2023 | 1496 | 0.940 |
Why?
| | Cough | 1 | 2024 | 122 | 0.840 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 81 | 0.830 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2828 | 0.800 |
Why?
| | Symporters | 1 | 2022 | 66 | 0.780 |
Why?
| | Lung Diseases | 2 | 2021 | 767 | 0.740 |
Why?
| | Anxiety Disorders | 1 | 2024 | 377 | 0.710 |
Why?
| | Risk Adjustment | 1 | 2021 | 78 | 0.700 |
Why?
| | Digestive System Surgical Procedures | 1 | 2022 | 106 | 0.690 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 402 | 0.690 |
Why?
| | Scleroderma, Systemic | 5 | 2024 | 122 | 0.690 |
Why?
| | Rectal Neoplasms | 1 | 2022 | 149 | 0.670 |
Why?
| | Humans | 71 | 2025 | 137585 | 0.670 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 460 | 0.660 |
Why?
| | Pyridones | 3 | 2023 | 168 | 0.650 |
Why?
| | Rheumatology | 4 | 2024 | 118 | 0.640 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 234 | 0.630 |
Why?
| | Family | 1 | 2023 | 671 | 0.610 |
Why?
| | Coronary Disease | 1 | 2021 | 385 | 0.600 |
Why?
| | Quality of Life | 3 | 2025 | 2892 | 0.580 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2023 | 97 | 0.580 |
Why?
| | Frailty | 1 | 2021 | 170 | 0.580 |
Why?
| | Aged | 25 | 2025 | 23961 | 0.570 |
Why?
| | Anxiety | 1 | 2024 | 1035 | 0.540 |
Why?
| | Health Personnel | 1 | 2023 | 710 | 0.530 |
Why?
| | Lung | 12 | 2023 | 4060 | 0.520 |
Why?
| | Middle Aged | 28 | 2025 | 33479 | 0.520 |
Why?
| | Respiratory Function Tests | 9 | 2025 | 600 | 0.510 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 350 | 0.510 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2016 | 38 | 0.510 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 617 | 0.500 |
Why?
| | Vital Capacity | 8 | 2025 | 311 | 0.460 |
Why?
| | Male | 35 | 2025 | 67762 | 0.440 |
Why?
| | Disease Progression | 7 | 2024 | 2757 | 0.430 |
Why?
| | Female | 35 | 2025 | 73304 | 0.400 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.400 |
Why?
| | Emphysema | 1 | 2013 | 106 | 0.390 |
Why?
| | Prognosis | 6 | 2021 | 4030 | 0.370 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2011 | 30 | 0.350 |
Why?
| | Smoking | 2 | 2017 | 1627 | 0.320 |
Why?
| | Sputum | 2 | 2025 | 311 | 0.320 |
Why?
| | Mortality | 3 | 2021 | 362 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2531 | 0.290 |
Why?
| | Double-Blind Method | 3 | 2023 | 1993 | 0.290 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2017 | 75 | 0.280 |
Why?
| | Fibrosis | 2 | 2023 | 552 | 0.280 |
Why?
| | Treatment Outcome | 6 | 2024 | 10811 | 0.270 |
Why?
| | Kaplan-Meier Estimate | 5 | 2018 | 889 | 0.270 |
Why?
| | Pulmonary Eosinophilia | 1 | 2006 | 27 | 0.250 |
Why?
| | Peptides, Cyclic | 3 | 2023 | 259 | 0.250 |
Why?
| | Lung Injury | 2 | 2024 | 219 | 0.250 |
Why?
| | Glucocorticoids | 3 | 2024 | 594 | 0.250 |
Why?
| | Narcotics | 1 | 2006 | 52 | 0.250 |
Why?
| | Risk Factors | 9 | 2024 | 10388 | 0.240 |
Why?
| | Radiation Injuries | 1 | 2006 | 145 | 0.230 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 50 | 0.220 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 890 | 0.210 |
Why?
| | Environmental Pollutants | 1 | 2006 | 159 | 0.210 |
Why?
| | Mucin-5B | 3 | 2025 | 224 | 0.210 |
Why?
| | Transforming Growth Factor beta | 2 | 2025 | 480 | 0.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 250 | 0.210 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 652 | 0.210 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 531 | 0.200 |
Why?
| | Immunomodulation | 1 | 2023 | 98 | 0.200 |
Why?
| | Survival Rate | 6 | 2019 | 1972 | 0.200 |
Why?
| | Fatigue | 1 | 2024 | 329 | 0.190 |
Why?
| | Rheumatologists | 1 | 2022 | 16 | 0.190 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5778 | 0.190 |
Why?
| | Plastics | 1 | 2022 | 42 | 0.190 |
Why?
| | Pandemics | 4 | 2024 | 1639 | 0.190 |
Why?
| | Sodium | 1 | 2022 | 217 | 0.180 |
Why?
| | Therapeutic Irrigation | 1 | 2022 | 77 | 0.180 |
Why?
| | HIV Infections | 1 | 2016 | 2836 | 0.180 |
Why?
| | Mental Status and Dementia Tests | 1 | 2021 | 26 | 0.180 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1910 | 0.180 |
Why?
| | Patient Care | 1 | 2022 | 111 | 0.180 |
Why?
| | Life Expectancy | 1 | 2021 | 69 | 0.170 |
Why?
| | Adult | 11 | 2024 | 37929 | 0.170 |
Why?
| | Serum Albumin | 1 | 2021 | 150 | 0.170 |
Why?
| | United States | 13 | 2024 | 14841 | 0.170 |
Why?
| | Cause of Death | 3 | 2019 | 434 | 0.170 |
Why?
| | Rectum | 1 | 2022 | 185 | 0.170 |
Why?
| | Neurosurgical Procedures | 1 | 2022 | 197 | 0.160 |
Why?
| | Attitude | 1 | 2022 | 259 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2021 | 179 | 0.160 |
Why?
| | Geriatric Assessment | 1 | 2021 | 224 | 0.160 |
Why?
| | Comorbidity | 2 | 2021 | 1622 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2021 | 7635 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 353 | 0.150 |
Why?
| | Sarcoidosis | 2 | 2011 | 159 | 0.150 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 36 | 0.150 |
Why?
| | Acute Disease | 1 | 2021 | 1007 | 0.150 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 293 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3284 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1509 | 0.140 |
Why?
| | Glucose | 1 | 2022 | 1020 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2021 | 3556 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1431 | 0.130 |
Why?
| | Registries | 1 | 2025 | 2035 | 0.130 |
Why?
| | Chaperonins | 1 | 2016 | 6 | 0.130 |
Why?
| | Ether-A-Go-Go Potassium Channels | 1 | 2016 | 6 | 0.130 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2017 | 49 | 0.130 |
Why?
| | Extracellular Traps | 1 | 2017 | 53 | 0.130 |
Why?
| | Pneumocystis carinii | 1 | 2016 | 12 | 0.130 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 29 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2844 | 0.120 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 175 | 0.120 |
Why?
| | Survival Analysis | 2 | 2017 | 1325 | 0.120 |
Why?
| | Pedigree | 1 | 2017 | 514 | 0.120 |
Why?
| | Granuloma | 1 | 2016 | 92 | 0.120 |
Why?
| | Critical Care | 1 | 2021 | 601 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1477 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 175 | 0.120 |
Why?
| | Thoracic Diseases | 1 | 2015 | 14 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1079 | 0.120 |
Why?
| | Health Care Costs | 1 | 2018 | 398 | 0.120 |
Why?
| | Emergency Medical Services | 1 | 2021 | 552 | 0.120 |
Why?
| | Mortality, Premature | 1 | 2013 | 14 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1291 | 0.100 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 69 | 0.100 |
Why?
| | Biomarkers | 2 | 2025 | 4149 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2013 | 117 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1266 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 332 | 0.100 |
Why?
| | Bronchial Diseases | 1 | 2012 | 37 | 0.090 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 367 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 852 | 0.090 |
Why?
| | Antigens, Human Platelet | 1 | 2011 | 9 | 0.090 |
Why?
| | Hospitalization | 1 | 2021 | 2199 | 0.090 |
Why?
| | Antibodies, Antinuclear | 1 | 2011 | 71 | 0.090 |
Why?
| | Cohort Studies | 2 | 2025 | 5742 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2025 | 15657 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 318 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 820 | 0.080 |
Why?
| | Bleomycin | 1 | 2011 | 248 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2013 | 313 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2012 | 234 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3457 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1502 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 226 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 795 | 0.070 |
Why?
| | Incidence | 3 | 2021 | 2804 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1719 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 293 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.070 |
Why?
| | Prevalence | 3 | 2021 | 2734 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1287 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1250 | 0.060 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.060 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 54 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 76 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2025 | 223 | 0.050 |
Why?
| | Young Adult | 5 | 2021 | 13209 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 554 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2426 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2006 | 395 | 0.050 |
Why?
| | Bronchi | 1 | 2024 | 260 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2023 | 115 | 0.050 |
Why?
| | Polymyositis | 1 | 2021 | 15 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2021 | 27 | 0.050 |
Why?
| | Sex Factors | 3 | 2013 | 2071 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 82 | 0.040 |
Why?
| | Sex Distribution | 2 | 2012 | 375 | 0.040 |
Why?
| | Biopsy | 2 | 2014 | 1129 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 740 | 0.040 |
Why?
| | Canada | 1 | 2021 | 418 | 0.040 |
Why?
| | Methotrexate | 1 | 2021 | 260 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 49 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2074 | 0.040 |
Why?
| | Insurance Claim Review | 1 | 2018 | 64 | 0.040 |
Why?
| | Forecasting | 1 | 2019 | 389 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5131 | 0.030 |
Why?
| | Disease Management | 1 | 2021 | 628 | 0.030 |
Why?
| | Hypersplenism | 1 | 2016 | 8 | 0.030 |
Why?
| | Leukopenia | 1 | 2016 | 31 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 73 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 386 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1070 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 95 | 0.030 |
Why?
| | Protein Folding | 1 | 2016 | 280 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 636 | 0.030 |
Why?
| | Adolescent | 3 | 2021 | 21513 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 811 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 622 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 730 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 26 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 822 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1916 | 0.030 |
Why?
| | Age Factors | 2 | 2011 | 3295 | 0.030 |
Why?
| | Medicare | 1 | 2018 | 773 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 67 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 121 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5472 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 49 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 76 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 106 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 560 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2010 | 75 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1357 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2224 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 392 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 530 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 452 | 0.020 |
Why?
| | Risk | 1 | 2011 | 912 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1024 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1793 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2011 | 762 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 6828 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5757 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7604 | 0.010 |
Why?
| | Mice | 1 | 2011 | 17787 | 0.010 |
Why?
| | Animals | 1 | 2011 | 36940 | 0.000 |
Why?
|
|
Solomon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|